ArticleEuropean journal of hospital pharmacy : science and practice2022
Antifungal drug resistance: an update.
Article in European journal of hospital pharmacy : science and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 90 citations in OpenAlex.
- Design, Synthesis, and Biological Evaluation of Trifluoromethylated 1,2,4-Triazin-6-ones with Selective Antimycotic Activity and Hormesis Effects.International journal of molecular sciences · 2026Article
- Clinical description and management of two terbinafine-resistant cases of tinea caused bySkin health and disease · 2026Article
- Outcomes Following Antifungal Treatment forJournal of fungi (Basel, Switzerland) · 2026Article
- Stress-Activated Protein Kinase Pathways as Potential Targets for the Development of New Antifungals.Journal of fungi (Basel, Switzerland) · 2026Review
- Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis.Microorganisms · 2026Review
- Comparative volatilomics identifies ubiquitous sulfur compounds inhibiting the fungal pathogenMicrobiology spectrum · 2026Article
- In Vivo Evaluation of Efficacy and Toxicity of Bioinspired Peptides With Antimicrobial Properties Against Fungal Infection inInternational journal of microbiology · 2026Article
- Investigation of azole resistance inJournal of medical microbiology · 2026Article
- Interconnected worlds: a comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics.IMA fungus · 2026Review
- Triazole-functionalized compounds as promising antifungal agents: Synthesis, biological evaluation, and mechanistic insights.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Next-generation antifungal peptide discovery: the synergy of artificial intelligence and omics technologies.World journal of microbiology & biotechnology · 2025Review
- Rosemary Extract: Phytochemical Composition and Potential for Eliminating Polymicrobial Biofilm ofBiotech (Basel (Switzerland)) · 2025Article
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- HybridPharmaceuticals (Basel, Switzerland) · 2025Article
- Is a Fungal Apocalypse Inevitable or Just a Hallucination? An Overview of the Antifungal Armamentarium Used in the Fight against Pathogenic Fungi.ACS medicinal chemistry letters · 2025Review
- Azole Antifungal Consumption in Community Pharmacy Sales in Mainland Portugal: Trend Analysis from 2014 to 2023.Antibiotics (Basel, Switzerland) · 2025Article
- BACTERIAL AND FUNGAL INFECTIONS IN PULMONARY TUBERCULOSIS PATIENTS AND THE DRUG SENSITIVITY TEST PATTERNS.African journal of infectious diseases · 2025Article
- Antimicrobial Multidrug Resistance and Mechanisms of Action: An Overview.BioMed research international · 2025Review
- Engineering Adhesion of the Probiotic StrainACS synthetic biology · 2024Article
- In vitro antifungal activities of medicinal plants used for treatment of candidiasis in Pader district, Northern Uganda.Tropical medicine and health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of antifungal classes is small, and resistance is becoming a much more frequent problem. Much greater emphasis needs to be placed on susceptibility testing and antifungal stewardship. Such efforts demonstrably improve survival and overall clinical outcomes. Positively diagnosing a fungal infection with laboratory markers often allows antibacterial therapy to be stopped (ie, anti-tuberculous therapy in chronic pulmonary aspergillosis or antibiotics other than cotrimoxazole in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.